Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

This study found that both fluoxetine and clomipramine are effective in treating psychogenic triggers of acral lick dermatitis in dogs, with fluoxetine leading to quicker recovery and lower recurrence rates, while clomipramine showed better overall recovery rates but was associated with fewer side effects.

This clinical case report describes a patient with ulcerative colitis whose symptoms improved using the Janus kinase inhibitor, tofacitinib, allowing disease remission and hair regrowth.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

This study reports three cases of alopecia areata resistant to corticosteroids that improved after 16 weeks of treatment with a combination of fractional carbon dioxide laser and topical tacrolimus, suggesting a potential new therapeutic option that requires further confirmation.

This study reported that a 10-week course of clindamycin and rifampicin was commonly used for treating folliculitis decalvans but the evidence on its efficacy remains inconclusive due to the low quality of available studies.

This study found that 1-day itraconazole therapy was more effective for acute vulvovaginal candidosis than for recurrent cases, where relapses occurred despite no yeast resistance.

This case report describes a 43-year-old male with alopecia totalis who successfully regrew all his hair after six months of treatment with tofacitinib, with no relapse at one year.

This study found that both Clomiphene Citrate and Human Chorionic Gonadotropin were effective in restoring testosterone levels in men with hypogonadism, as demonstrated in a short-course randomized study.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This study found that intralesional triamcinolone was more effective than topical betamethasone for hair regrowth in patients with localized alopecia areata.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This study found that adding pulsed prednisone to tofacitinib was linked to sustained hair regrowth in alopecia areata patients not responding to tofacitinib alone.

This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.

In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.

This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.

This review discusses systemic antifungal treatments for tinea capitis in children, noting that newer agents like terbinafine and itraconazole require shorter courses than the traditional griseofulvin, but may be more costly.

This study reports a case of a 59-year-old female with refractory follicular mucinosis and diffuse scalp alopecia who achieved complete clinical remission following treatment with a combination of topical tacalcitol and photodynamic therapy.

This source highlights that topical retinoids, particularly adapalene and its combinations, are crucial in treating acne due to their rapid action, sustained effects, and good tolerability; the study underscores the enhanced patient adherence with Deriva C MS gel for acne treatment.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

In this study, a risk score was developed and validated to identify patients at high risk of clinical failure after femoropopliteal peripheral vascular intervention, aiming to guide the selection of patients who may benefit from paclitaxel-coated devices or alternative strategies.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.